A Study to Evaluate the Safety and Efficacy of BOL-DP-o-08 in Patients With Endometriosis Syndrome

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Subjects diagnosed with Endometriosis will be eligible for enrollment. During a Screening Period of 2 weeks, inclusion and exclusion criteria will be assessed to determine if they are eligible to move into the Treatment Period. During Treatment, subjects will randomly receive either BOL‐DP‐o‐08 or placebo TID for 16 weeks. At the end of the treatment, a follow‐up visit for safety assessments will be conducted 4 weeks after the termination visit.
Epistemonikos ID: a4ee661e1f3ba39e9bc167b972cb3a4d6444af00
First added on: May 06, 2024